No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - Baseline findings of a multicenter trial

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Umeh, Chizoba C ^a   Pérez, Adriana ^b   Augustine, Erika F ^c   Dhall, Rohit ^d   Dewey, Richard B ^e   Mari, Zoltan ^f   Simon, David K ^g   Wills, Anne Marie A ^a   Christine, Chadwick W ^h   Schneider, Jay S ⁱ   Suchowersky, Oksana ^j  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d BARROW NEUROLOGICAL INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ THOMAS JEFFERSON UNIVERSITY   (United States)

^j UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; RASAGILINE; TRIHEXYPHENIDYL;

ADULT; ARTICLE; BODY WEIGHT; CANADA; DAILY LIFE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; SECONDARY ANALYSIS; SEX DIFFERENCE; UNIFIED PARKINSON DISEASE RATING SCALE; UNITED STATES; AGED; CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; CANADA; DOPAMINE AGENTS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84915749778     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112287     Document Type: Article

References (21)

1. Hoffmann DE, Tarzian AJ (2001) The girl who cried pain: a bias against women in the treatment of pain. J Law Med Ethics 29: 13-27.
2. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, et al. (2005) Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromesLarge-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. Journal of the American College of Cardiology 45: 832-837.
3. Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, et al. (2008) Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol 7: 915-926.
4. Baba Y, Putzke JD, Whaley NR, Wszolek ZK, Uitti RJ (2005) Gender and the Parkinson's disease phenotype. Journal of Neurology 252: 1201-1205.
5. Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, et al. (2007) Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry 78: 819-824.
6. Nyholm D, Karlsson E, Lundberg M, Askmark H (2010) Large differences in levodopa dose requirement in Parkinson's disease: men use higher doses than women. Eur J Neurol 17: 260-266.
7. Lyons KE, Hubble JP, Tröster AI, Pahwa R, Koller WC (1998) Gender differences in Parkinson's disease. Clin Neuropharmacol 21: 118-121.
8. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, et al. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342: 1484-1491.
9. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, et al. (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351: 2498-2508.
10. Elm JJ, The NNETPDI (2012) Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord 27: 1513-1521.
11. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, et al. (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25: 2649-2653.
12. Box GEP, Cox DR (1964) An Analysis of Transformations. J R Stat Soc Series B 26: 211-252.
13. Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 39: 37-45.
14. Shulman LM, Bhat V (2006) Gender disparities in Parkinson's disease. Expert Rev Neurother 6: 407-416.
15. Zappia M, Crescibene L, Arabia G, Nicoletti G, Bagala A, et al. (2002) Body weight influences pharmacokinetics of levodopa in Parkinson's disease. Clin Neuropharmacol 25: 79-82.
16. Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, et al. (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 28: 1064-1071.
17. (2011) A randomized pilot trial of estrogen replacement therapy in post-menopausal women with Parkinson's disease. Parkinsonism Relat Disord 17: 757-760.
18. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, et al. (1999) The effect of estrogen replacement on early Parkinson's disease. Neurology 52: 1417-1421.
19. Tsang KL, Ho SL, Lo SK (2000) Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 54: 2292-2298.
20. Session DR, Pearlstone MM, Jewelewicz R, Kelly AC (1994) Estrogens and Parkinson's disease. Med Hypotheses 42: 280-282.
21. Willis AW, Schootman M, Kung N, Wang XY, Perlmutter JS, et al. (2014) Disparities in deep brain stimulation surgery among insured elders with Parkinson disease. Neurology 82: 163-171.